Roman J.
- Country
- Poland
- Department
- Nie dotyczy
Research Overview
- Efficacy and Safety of Zenagamtide in Participants with Overweight or Obesity and Knee Osteoarthritis
- Long-Term Extension Study of Imeroprubart in Adult Patients With Graves' Disease
- Phase 3 Randomized Double‑Masked Placebo‑Controlled Study of Subcutaneous Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs
Data & Insights
Has run more than one trial at 61 of 227 partner sites.
Specializations
Cardiometabolic and atherosclerotic cardiovascular disease
Roman Junik is involved in clinical research focused on cardiovascular risk reduction, lipid disorders, hypertension, atrial fibrillation, and heart failure, with additional interest in peripheral arterial disease and elevated lipoprotein(a).
- Major adverse cardiovascular events
- Mixed dyslipidemia and high cardiovascular risk
- Heart failure with preserved or mildly reduced ejection fraction
- Primary prevention of atherosclerotic cardiovascular disease
The therapeutic emphasis includes prevention of cardiovascular events, treatment of heart failure, and management of metabolic contributors to vascular disease.
Metabolic disease and obesity
His research landscape includes type 2 diabetes mellitus, type 1 diabetes, overweight, obesity, and related cardiometabolic complications such as obesity-associated heart failure and knee osteoarthritis.
- Type 2 diabetes mellitus
- Obesity and overweight
- Obesity-related cardiovascular outcomes
- Weight management with musculoskeletal comorbidity
Therapeutic interest extends to interventions addressing glycaemic control, body weight, and downstream metabolic risk.
Autoimmune, inflammatory, and endocrine disorders
Roman Junik is also active in studies of systemic lupus erythematosus, lupus nephritis, primary Sjögren’s disease, psoriatic arthritis, and Graves’ disease, alongside acromegaly.
- Systemic lupus erythematosus and lupus nephritis
- Primary Sjögren’s disease
- Psoriatic arthritis
- Graves’ disease and acromegaly
The therapeutic focus covers immune-mediated disease control, renal involvement, and endocrine regulation.
Hepatic, renal, and liver-related metabolic disease
His trial portfolio includes non-alcoholic steatohepatitis, alcohol-related liver disease, and renal complications linked to heart failure and systemic autoimmune disease.
- Non-alcoholic steatohepatitis
- Alcohol-related liver disease
- Active proliferative lupus nephritis
- Kidney function impairment in heart failure
These areas reflect interest in therapies targeting liver injury, renal preservation, and multi-organ metabolic disease.
Neurologic, psychiatric, and pain conditions
Roman Junik’s research also spans alcohol addiction, major depressive disorder with insomnia symptoms, chronic non-specific low back pain, and osteoarthritis, including pain associated with excess body weight.
- Alcohol use disorder
- Major depressive disorder with insomnia
- Chronic low back pain
- Knee osteoarthritis
The therapeutic scope includes symptom relief, functional improvement, and treatment of comorbid pain and behavioral health disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.